Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

Serving hundreds of leading biopharmaceutical companies globally:

Deloitte
Argus Health
AstraZeneca
Federal Trade Commission
Cerilliant
Express Scripts
Johnson and Johnson
Cantor Fitzgerald
Merck

Generated: June 21, 2018

DrugPatentWatch Database Preview

Details for Patent: 8,999,999

« Back to Dashboard

Summary for Patent: 8,999,999
Title:Use of inhibitors of Bruton's tyrosine kinase (Btk)
Abstract: Disclosed herein are methods for treating a cancer comprising: a. administering a Btk inhibitor to a subject sufficient to result in an increase or appearance in the blood of a subpopulation of lymphocytes defined by immunophenotyping; b. determining the expression profile of one or more biomarkers from one or more subpopulation of lymphocytes; and c. administering a second agent based on the determined expression profile.
Inventor(s): Buggy; Joseph J. (Mountain View, CA), Elias; Laurence (Berkeley, CA), Fyfe; Gwen (San Francisco, CA), Hedrick; Eric (Summit, NJ), Loury; David J. (San Jose, CA), Mody; Tarak D. (Sunnyvale, CA)
Assignee: Pharmacyclics, Inc. (Sunnyvale, CA)
Application Number:13/747,322
Patent Claim Types:
see list of patent claims
Use; Delivery; Dosage form;

Drugs Protected by US Patent 8,999,999

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Patented / Exclusive Use Patent Submitted
Pharmacyclics Inc IMBRUVICA ibrutinib CAPSULE;ORAL 205552-002 Dec 20, 2017 RX Yes No ➤ Sign Up ➤ Sign Up TREATMENT OF SMALL LYMPHOCYTIC LEUKEMIA ➤ Sign Up
Pharmacyclics Inc IMBRUVICA ibrutinib CAPSULE;ORAL 205552-002 Dec 20, 2017 RX Yes No ➤ Sign Up ➤ Sign Up TREATMENT OF CHRONIC LYMPHOCYTIC LEUKEMIA ➤ Sign Up
Pharmacyclics Inc IMBRUVICA ibrutinib CAPSULE;ORAL 205552-002 Dec 20, 2017 RX Yes No ➤ Sign Up ➤ Sign Up TREATMENT OF SMALL LYMPHOCYTIC LYMPHOMA ➤ Sign Up
Pharmacyclics Inc IMBRUVICA ibrutinib CAPSULE;ORAL 205552-001 Nov 13, 2013 RX Yes Yes ➤ Sign Up ➤ Sign Up TREATMENT FOR CHRONIC LYMPHOCYTIC LEUKEMIA WITH 17P DELETION ➤ Sign Up
Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Patented / Exclusive Use Patent Submitted

This preview shows a limited data set. Subscribe for full access, or try a Free Trial

Non-Orange Book US Patents Family Members for Patent 8,999,999

For Orange Book-listed patents (shown in the main table above) generic applications must certify that the listed patents are expired, invalid, or will not be infringed by generic entry.

The non-Orange Book patents listed below do not require formal certifications, so they do not automatically impede generic entry. Instead, they represent potential opportunities for branded firms to block generic entry through patent infringment challenges.

Patent No. Title Estimated Patent Expiration
9,801,883 Use of inhibitors of bruton's tyrosine kinase (Btk) ➤ Sign Up
8,754,090 Use of inhibitors of bruton's tyrosine kinase (Btk) ➤ Sign Up
9,814,721 Use of inhibitors of bruton'S tyrosine kinase (BTK) ➤ Sign Up
9,801,881 Use of inhibitors of bruton's tyrosine kinase (BTK) ➤ Sign Up
Patent No. Title Estimated Patent Expiration

This preview shows a limited data set. Subscribe for full access, or try a Free Trial

For more information try a trial or see the plans and pricing

Serving hundreds of leading biopharmaceutical companies globally:

Express Scripts
Covington
Accenture
Healthtrust
Queensland Health
Chinese Patent Office
Julphar
McKinsey
Johnson and Johnson

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.